BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23070984)

  • 21. Electrocardiographic QRS Fragmentation as a Marker for Myocardial Fibrosis in Hypertrophic Cardiomyopathy.
    Konno T; Hayashi K; Fujino N; Oka R; Nomura A; Nagata Y; Hodatsu A; Sakata K; Furusho H; Takamura M; Nakamura H; Kawashiri MA; Yamagishi M
    J Cardiovasc Electrophysiol; 2015 Oct; 26(10):1081-7. PubMed ID: 26102305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Choi HM; Kim KH; Lee JM; Yoon YE; Lee SP; Park EA; Lee W; Kim YJ; Cho GY; Sohn DW; Kim HK
    Heart; 2015 Jun; 101(11):870-6. PubMed ID: 25897040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction.
    Ellims AH; Iles LM; Ling LH; Hare JL; Kaye DM; Taylor AJ
    J Cardiovasc Magn Reson; 2012 Oct; 14(1):76. PubMed ID: 23107451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation.
    Papavassiliu T; Germans T; Flüchter S; Doesch C; Suriyakamar A; Haghi D; Süselbeck T; Wolpert C; Dinter D; Schoenberg SO; van Rossum AC; Borggrefe M
    J Cardiovasc Magn Reson; 2009 Sep; 11(1):34. PubMed ID: 19740409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-wave and its association with myocardial fibrosis on cardiovascular magnetic resonance examination.
    Zareba KM; Truong VT; Mazur W; Smart SM; Xia X; Couderc JP; Raman SV
    Ann Noninvasive Electrocardiol; 2021 Mar; 26(2):e12819. PubMed ID: 33336876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy.
    Almaas VM; Haugaa KH; Strøm EH; Scott H; Smith HJ; Dahl CP; Geiran OR; Endresen K; Aakhus S; Amlie JP; Edvardsen T
    Heart; 2014 Apr; 100(8):631-8. PubMed ID: 24368281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late gadolinium enhancement of cardiac magnetic resonance imaging indicates abnormalities of time-domain T-wave alternans in hypertrophic cardiomyopathy with ventricular tachycardia.
    Sakamoto N; Sato N; Oikawa K; Karim Talib A; Sugiyama E; Minoshima A; Tanabe Y; Takeuchi T; Akasaka K; Saijo Y; Kawamura Y; Hasebe N
    Heart Rhythm; 2015 Aug; 12(8):1747-55. PubMed ID: 25916568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy.
    Urbano-Moral JA; Rowin EJ; Maron MS; Crean A; Pandian NG
    Circ Cardiovasc Imaging; 2014 Jan; 7(1):11-9. PubMed ID: 24275954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitral annular plane systolic excursion is an easy tool for fibrosis detection by late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Doesch C; Sperb A; Sudarski S; Lossnitzer D; Rudic B; Tülümen E; Heggemann F; Schimpf R; Schoenberg SO; Borggrefe M; Papavassiliu T
    Arch Cardiovasc Dis; 2015; 108(6-7):356-66. PubMed ID: 25863428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of left ventricular dyssynchrony on gated myocardial perfusion SPECT analysis with extent of late gadolinium enhancement on cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.
    Yuki H; Utsunomiya D; Shiraishi S; Takashio S; Sakamoto F; Tsuda N; Oda S; Kidoh M; Nakaura T; Tsujita K; Yamashita Y
    Heart Vessels; 2018 Jun; 33(6):623-629. PubMed ID: 29230571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation the relationship between myocardial fibrosis and left ventricular torsion measured by cardiac magnetic resonance feature-tracking in hypertrophic cardiomyopathy patients with preserved ejection fraction.
    Zhong Y; Li C; Yu Y; Du Y; Bai Y; Wang X; Dai X; Fan G; Wang G
    Int J Cardiovasc Imaging; 2024 Apr; 40(4):921-930. PubMed ID: 38448705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.
    Wu LM; Chen BH; Yao QY; Ou YR; Wu R; Jiang M; Hu J; An DA; Xu JR
    Int J Cardiovasc Imaging; 2016 Aug; 32(8):1289-97. PubMed ID: 27198892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
    Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
    J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study.
    Delcrè SD; Di Donna P; Leuzzi S; Miceli S; Bisi M; Scaglione M; Caponi D; Conte MR; Cecchi F; Olivotto I; Gaita F
    Int J Cardiol; 2013 Aug; 167(3):1038-45. PubMed ID: 22464482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Myocardial Disarray in Patients With Hypertrophic Cardiomyopathy and Ventricular Arrhythmias.
    Ariga R; Tunnicliffe EM; Manohar SG; Mahmod M; Raman B; Piechnik SK; Francis JM; Robson MD; Neubauer S; Watkins H
    J Am Coll Cardiol; 2019 May; 73(20):2493-2502. PubMed ID: 31118142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy.
    Dass S; Suttie JJ; Piechnik SK; Ferreira VM; Holloway CJ; Banerjee R; Mahmod M; Cochlin L; Karamitsos TD; Robson MD; Watkins H; Neubauer S
    Circ Cardiovasc Imaging; 2012 Nov; 5(6):726-33. PubMed ID: 23071146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Clinical Prognosis of Presence and Location of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: a Single-Center Cohort Study.
    Li X; Lai L; Luo R; Yang H; Ma H; Yang Z; Zhao S; Su W; Hua W
    J Cardiovasc Transl Res; 2021 Oct; 14(5):1001-1016. PubMed ID: 33629154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
    Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR.
    Moravsky G; Ofek E; Rakowski H; Butany J; Williams L; Ralph-Edwards A; Wintersperger BJ; Crean A
    JACC Cardiovasc Imaging; 2013 May; 6(5):587-96. PubMed ID: 23582356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.